$LOXO Reiterated with a buy at Piper $200 PT, saying Loxo's 292 appears to be the superior RET inhibitor in development, both in terms of efficacy and safety $BPMC
More From BioPortfolio on "$LOXO Reiterated with a buy at Piper $200 PT, saying Loxo's 292 appears to be the superior RET inhibitor in development, both in terms of efficacy and safety $BPMC"